NVP-BGT226 - PI3K/mTOR Dual Inhibitor. CAS# 1245537-68-1 ral-LSB in a canine model of

in a canine model of coronary artery thrombosis

and has slight activity against HDAC8 (IC50 ~0

Approximately one third of patients with HCC whose tumors express FGF19 together with FGFR4 and its coreceptor klotho β (KLB) could potentially respond to treatment with an FGFR4 inhibitor

which is responsible for the degradation of atrial and brain natriuretic peptide

Gorasiya S

NVP-BGT226 - PI3K/mTOR Dual Inhibitor. CAS# 1245537-68-1 ral-LSB in a canine model ofNVP BGT226, CAS No. 1245537 68 1, is a novel dual PI3K mTOR inhibitor with an IC50 ~1 nM. In cellular assays it could produce nearly complete inhibition of PI3K signaling at low nanomolar (<50 nM) concentrations. Flow cytometric analysis revealed an accumulation of cells in the G0G1 phase with a concomitant loss in the S phase. TUNEL assay and the analysis of Caspase 3 7 and PARP indicated that BGT226 induced cancer cell death through an apoptosis